Franklin Resources Inc. decreased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 24.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 97,538 shares of the biopharmaceutical company's stock after selling 31,447 shares during the quarter. Franklin Resources Inc. owned 0.06% of TG Therapeutics worth $2,936,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 1,737 shares in the last quarter. Synergy Asset Management LLC purchased a new stake in shares of TG Therapeutics in the fourth quarter valued at about $75,000. Finally, GAMMA Investing LLC lifted its position in shares of TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 2,171 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have commented on TGTX shares. HC Wainwright reiterated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $40.67.
Check Out Our Latest Report on TG Therapeutics
TG Therapeutics Stock Performance
NASDAQ TGTX traded up $0.62 on Tuesday, hitting $39.03. 1,600,072 shares of the stock traded hands, compared to its average volume of 3,110,681. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of -390.26 and a beta of 2.14. The business's fifty day moving average is $35.98 and its two-hundred day moving average is $31.60. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Read More
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
